[
    [
        {
            "time": "",
            "original_text": "资金流跟踪系列二十五：上资金会重复一季度的大幅外流之势吗？",
            "features": {
                "keywords": [
                    "资金流",
                    "一季度",
                    "大幅外流"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "资金流跟踪系列二十五：上资金会重复一季度的大幅外流之势吗？",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "【异动股】药明康德(02359-HK)跌3.01%",
            "features": {
                "keywords": [
                    "异动股",
                    "药明康德",
                    "下跌"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "【异动股】药明康德(02359-HK)跌3.01%",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 7,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "芯片股巨震！但板块内这些股票大涨20%",
            "features": {
                "keywords": [
                    "芯片股",
                    "巨震",
                    "大涨"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "芯片股巨震！但板块内这些股票大涨20%",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 8,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "民生证券医药行业周报：关注高景气医疗器械以及低估值板块机会",
            "features": {
                "keywords": [
                    "医药行业",
                    "高景气",
                    "医疗器械",
                    "低估值"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "民生证券医药行业周报：关注高景气医疗器械以及低估值板块机会",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "融资客青睐7股，中源协和买入占比高达39.51%",
            "features": {
                "keywords": [
                    "融资",
                    "中源协和",
                    "买入占比"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物技术"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "融资客青睐7股，中源协和买入占比高达39.51%",
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "医药生物：关注估值切换带来低估值板块投资机遇",
            "features": {
                "keywords": [
                    "医药生物",
                    "估值切换",
                    "低估值"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "医药生物：关注估值切换带来低估值板块投资机遇",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "【港股医药2020年中报总结】上半年CRO一枝独秀，下半年行业全面恢复可期",
            "features": {
                "keywords": [
                    "港股医药",
                    "CRO",
                    "全面恢复"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "【港股医药2020年中报总结】上半年CRO一枝独秀，下半年行业全面恢复可期",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 4,
                "Headline_Structure": 8,
                "Source_Recency": 4
            }
        }
    ]
]